个人简介：
张列峰，女，博士，生物化学与分子生物学专业，主要研究方向：核酸、蛋白等生化药物的递送及其机制研究，硕士生导师，指导硕士研究生多人获得校朱敬文奖学金，国家奖学金等。
教学成果：
2019年校本科教学优秀成果二等奖；2020年校优秀班主任称号；2022年校本科教学优秀成果一等奖。2021年校级教改项目一项，2022年校级课程思政示范课程。
近年来发表论文：
(1)Yanru Qin, Zhongjie Wang, Xueyuan Wang, Tianyu Zhang, Yixue Hu, Dongna Wang, Hui Sun, Liefeng Zhang*, Yongqiang Zhu*. Therapeutic effect of multifunctional celastrol nanoparticles with mitochondrial alkaline drug release in breast cancer. Materials Today Advances 2023, 17: 100328.
(2)Zhimeng Chen, Tiantian Wen, Xueyuan Wang, Lin Yang, Zhongjie Wang, Yanru Qin, Yixue Hu, Tianyu Zhang, Dongna Wang, Amin Liu, Liefeng Zhang*, Meng Lei*, Yongqiang Zhu*. Co-delivery of immunochemotherapeutic by classified targeting based on chitosan and cyclodextrin derivatives. International Journal of Biological Macromolecules 2023, 226: 1396–1410.
(3)Zhongjie Wang, Yanru Qin, Xueyuan Wang, Tianyu Zhang, Yixue Hu, Dongna Wang, Liefeng Zhang*, Yongqiang Zhu*.Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer. International Journal of Nanomedicine 2023,18: 4023–4042.
(4)Tiantian Wei, Yin Zhang , Meng Lei, Yanru Qin, Zhongjie Wang, Zhimeng Chen, Liefeng Zhang*, Yongqiang Zhu*.Development of oral curcumin based on pH-responsive transmembrane peptide-cyclodextrin derivative nanoparticles for hepatoma. Carbohydrate Polymers 277 (2022) 118892.
(5) Xiaoyan Wu#, Yingying Hua#, Tiantian Wei, Chenjun Ma, Zhongjie Wang, Liefeng Zhang*, Jing Wang*. Effect and mechanism of action in vitro of cyclodextrin derivative nanoparticles loaded with tyroserleutide on hepatoma, Nanotechnology 2021,32: 285101
(6) Chenjun Ma, Tiantian Wei, Zhongjie Wu, Tiantian Wei, Liefeng Zhang*. Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma. International Journal of Nanomedicine 2021:16 4495–4513.
(7) Manman Li, Yusheng Sun, Chenjun Ma, Yingying Hua, Liefeng Zhang*, Jian Shen *. Design and investigation of penetrating mechanism of octaarginine-modified alginate nanoparticles for improving intestinal insulin delivery, Journal of Pharmaceutical Sciences, 2021, 110: 268-279.
(8) Yusheng Sun, Chenjun Ma, Yingying Hua, Tiantian Wei, Liefeng Zhang*. Multifunctional nanoparticles of paclitaxel and cyclodextrin-polypeptide conjugates within vitro anticancer activity. Pharmaceutical Development and Technology, 2020, 25: 1071-1080.
(9) Yingying Hua, Chenjun Ma, Tiantian Wei, Liefeng Zhang *, Jian Shen*. Collagen/Chitosan Complexes: Preparation, Antioxidant Activity, Tyrosinase Inhibition Activity, and Melanin Synthesis. International Journal of Molecular Sciences, 2020,21, 313.
(10) Manman Li#, Mei Han#, Yusheng Sun, Yingying Hua, Guifang Chen *, Liefeng Zhang*. Oligoarginine mediated collagen/chitosan gel composite for cutaneous wound healing. International Journal of Biological Macromolecules, 2019, 122: 1120-1127.
(11) Hongxue Shen, Yi Liu, Huanhuan Zhang, Pinggang Ding, Lan Zhang, Liefeng Zhang*, Jianming Ju*. Enhancing the oral bioavailability of baicalein via Solutol®HS15 and Poloxamer 188 mixed micelles system. Journal of Pharmacy and Pharmacology, 2019, 71: 765-773.
(12) Liuqing Yang, Manman Li, Yusheng Sun, Liefeng Zhang*. A cell-penetrating peptide conjugated carboxymethyl-β-cyclodextrin to improve intestinal absorption of insulin. International Journal of Biological Macromolecules, 2018, 111: 685-695.
(13) Lei Li, Liaoqing Yang, Manman Li, Yusheng Sun, Liefeng Zhang*. A cell penetrating peptide mediated chitosan nanocarriers forimproving intestinal insulin delivery. Carbohydrate Polymers, 2017,174: 182-189.
承担科研项目情况：
1、江苏省生物医药功能材料协同创新中心面上项目，肿瘤靶向穿膜肽-环糊精的合成及其介导酪丝亮肽的抗肿瘤研究。
2、国家自然科学基金面上项目，81573337，N-脂酰化对抗菌肽CM4选择性抗癌的影响与分子机制研究，2016/01—2019/12，64.4万元，结题，参与。
3、江苏省生物学优势学科“青年教师提升计划”，新型穿膜肽的筛选及其功能研究，2014/01-2016/12,8万元，已结题，主持。
4、国家自然科学基金青年基金，81302688，两亲性脂肽介导的胰岛素转运及其穿膜机理研究，2014/01—2016/12，23万元，已结题，主持。
5、教育部博士点基金（新教师系列），20103207120008，新型穿膜肽口服递送胰岛素环糊精超分子及其生物利用度的研究，2011/01—2013/12，3.8万元，已结题，主持。
6、国家博士后特别资助基金，200902524，胰岛素超分子及其非注射给药的研究，2009/01-2012/03，10万元，已结题，主持。
